Please login to the form below
Immunomedics
This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.
EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer
Trodelvy, which Gilead acquired as part of its $21bn buyout of Immunomedics, is an antibody-drug conjugate (ADC) targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumours
Latest news
-
Kite and Oxford BioTherapeutics sign oncology research pact
The separation allowed Gilead to focus on its other oncology projects and programmes – which now include its most recent oncology buyout of Immunomedics for $12bn. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of
-
Gilead agrees $21bn buyout of Immunomedics
The transaction will see Gilead purchase Immunomedics for $88 per share, for a total value of $21bn, and is expected to close during the fourth quarter of the year. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of
-
Immunomedics craters after FDA rejects breast cancer ADC
Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... Immunomedics’ management also expressed surprise at the rejection,
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried
-
Seattle Genetics claims key US approval for Adcetris
The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO
More from news
Approximately 5 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
the first siRNA-based inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) to win approval; and Immunomedics’s sacituzumab govitecan, which is poised become the first antibody-drug conjugate to ... 9. Immunomedic’s sacituzumab govitecan
-
Deal Watch January 2018
Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... The whole episode resulted in the resignation of the Immunomedics CEO and CSO.
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals during October 2013
The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... On termination, all rights revert back to Immunomedics and it is expected that arbitration will continue in parallel with
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
